Surgery and OncologySurgery and OncologyХирургия и онкология2949-5857Publishing House ABV Press75410.17650/2949-5857-2024-14-4-31-42LITERATURE REVIEWОБЗОР ЛИТЕРАТУРЫMetastatic colon cancer: clinical practice guideline update in 2024Метастатический рак толстой кишки: обновление клинических рекомендаций в 2024 г.https://orcid.org/0000-0001-5615-7806FedyaninM. Yu.ФедянинМ. Ю.
Russian Federation

Mikhail Yu.Fedyanin

24 Kashirskoe Shosse, Moscow 115522,

8 Sosenskiy Stan St., Moscow 108801,

70 Nizhnyaya Pervomayskaya St., Moscow 105203

Михаил Юрьевич Федянин 

115522 Москва, Каширское шоссе, 24,

108801 п. Коммунарка, ул. Сосенский стан, 8,

105203 Москва, ул. Нижняя Первомайская, 7

fedianinmu@mail.ruhttps://orcid.org/0000-0003-1367-2079GladkovO. A.ГладковО. А.
Russian Federation

9V Bluchera St., Chelyabinsk 454048, Russia;

42 Bluchera St., Chelyabinsk 454087

454048 Челябинск, ул. Блюхера, 9В;

454087 Челябинск, ул. Блюхера, 42

https://orcid.org/0000-0002-9303-8379GordeevS. S.ГордеевС. С.
Russian Federation

24 Kashirskoe Shosse, Moscow 115522,

54 Odesskaya St., Tyumen 625023

115522 Москва, Каширское шоссе, 24,

625023 Тюмень, ул. Одесская, 54

https://orcid.org/0000-0001-6641-7229KarachunA. M.КарачунА. М.
Russian Federation

68 Leningradskaya St., Pesochnyy Settlement, Saint Petersburg 197758,

41 Kirochnaya St., Saint-Petersburg 191015

197758 Санкт-Петербург, п. Песочный, ул. Ленинградская, 68,

191015 Санкт-Петербург, ул. Кирочная, 41

https://orcid.org/0000-0003-3852-3969KozlovN. A.КозловН. А.
Russian Federation

24 Kashirskoe Shosse, Moscow 115522

115522 Москва, Каширское шоссе, 24

https://orcid.org/0000-0002-9289-1247MamedliZ. Z.МамедлиЗ. З.
Russian Federation

24 Kashirskoe Shosse, Moscow 115522

115522 Москва, Каширское шоссе, 24

RykovI. V.РыковИ. В.
Russian Federation

2 Akkuratova St., Saint-Petersburg 197341

197341 Санкт-Петербург, ул. Аккуратова, 2

https://orcid.org/0000-0003-2245-214XTryakinA. A.ТрякинА. А.
Russian Federation

24 Kashirskoe Shosse, Moscow 115522

115522 Москва, Каширское шоссе, 24

https://orcid.org/0000-0001-8571-7462TsukanovA. S.ЦукановА. С.
Russian Federation

2 Salyama Adilya St., Moscow 123423

123423 Москва, ул. Саляма Адиля, 2

ChernykhM. V.ЧерныхМ. В.
Russian Federation

24 Kashirskoe Shosse, Moscow 115522,

8/2 Trubetskaya St., Moscow 119048

115522 Москва, Каширское шоссе, 24,

119048 Москва, ул. Трубецкая, 8/2

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава РоссииMoscow Multidisciplinary Clinical Center “Kommunarka”, Moscow Healthcare DepartmentГБУЗ г. Москвы «Московский многопрофильный клинический центр «Коммунарка» Департамента здравоохранения г. Москвы»National Medical and Surgical Center named after N.I. Pirogov, Ministry of Health of RussiaФГБУ «Национальный медико-хирургический центр им. Н.И. Пирогова» Минздрава РоссииMedical Oncology Center “EVIMED”Медицинский онкологический центр «ЭВИМЕД»Chelyabinsk Regional Clinical Center of Oncology and Nuclear MedicineГАУЗ «Челябинский областной клинический центр онкологии и ядерной медицины»Tyumen State Medical University, Ministry of Health of RussiaФГБОУ ВО «Тюменский государственный медицинский университет» Минздрава РоссииN.N. Petrov National Medical Research Center of Oncology, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Петрова» Минздрава РоссииNorth-Western State Medical University named after I.I. Mechnikov, Ministry of Health of RussiaФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И. Мечникова» Минздрава РоссииAlmazov National Medical Research Center, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр им. В.А. Алмазова» Минздрава РоссииRyzhikh National Medical Research Center of Coloproctology, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр колопроктологии им. А.Н. Рыжих» Минздрава РоссииI.M. Sechenov First Moscow State Medical University, Ministry of Health of RussiaФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)3011202414431422911202429112024Copyright ©; 2024, Fedyanin M.Y., Gladkov O.A., Gordeev S.S., Karachun A.M., Kozlov N.A., Mamedli Z.Z., Rykov I.V., Tryakin A.A., Tsukanov A.S., Chernykh M.V.Copyright ©; 2024, Федянин М.Ю., Гладков О.А., Гордеев С.С., Карачун А.М., Козлов Н.А., Мамедли З.З., Рыков И.В., Трякин А.А., Цуканов А.С., Черных М.В.2024Fedyanin M.Y., Gladkov O.A., Gordeev S.S., Karachun A.M., Kozlov N.A., Mamedli Z.Z., Rykov I.V., Tryakin A.A., Tsukanov A.S., Chernykh M.V.Федянин М.Ю., Гладков О.А., Гордеев С.С., Карачун А.М., Козлов Н.А., Мамедли З.З., Рыков И.В., Трякин А.А., Цуканов А.С., Черных М.В.https://creativecommons.org/licenses/by/4.0https://onco-surgery.info/jour/article/view/754

This article presents changes to clinical guidelines for the treatment of metastatic colon cancer in 2024. The new provisions in the clinical guidelines are complemented by a brief overview of the research results that underlie them. The changes considered concern not only systemic antitumor treatment, but also surgery and molecular genetic diagnostics. The differences between the recommendations of RUSSCO and the Ministry of Health of Russia are given. The introduction of information to determine the clinical benefit of expensive therapeutic options in relation to the use of the ESMO-MCBS and RUSSCO-MCBS scales is discussed.

Aim. Bringing information to a wide range of readers on planned changes in clinical guidelines.

В статье представлены изменения клинических рекомендаций по лечению метастатического рака толстой кишки в 2024 г. Новые положения в клинических рекомендациях дополнены кратким обзором результатов исследований, которые лежат в их основе. Рассмотренные изменения касаются не только системного противоопухолевого лечения, но и хирургии и молекулярно-генетической диагностики. Приведены отличия рекомендаций RUSSCO и Минздрава России. Обсуждается внесение информации по определению клинической пользы дорогостоящих терапевтических опций в отношении применения шкал ESMO-MCBS и RUSSCO-MCBS.

Цель исследования – предоставить обзор информации для широкого круга читателей по планируемым изменениям в клинических рекомендациях, касающихся метастатического рака толстой кишки.

rectal cancercolon cancercolorectal cancerclinical guidelineschemotherapytargeted therapyimmunotherapyliver transplantationрак прямой кишкирак ободочной кишкиколоректальный ракклинические рекомендациихимиотерапиятаргетная терапияиммунотерапиятрансплантация печениOsterlund P., Salminen T., Soveri L.-M. et al. Repeated centralized multidisciplinary team assessment of resectability, clinical behavior, and outcomes in 1086 Finnish metastatic colorectal cancer patients (RAXO): A nationwide prospective intervention study. Lancet Reg Health Eur 2021;3:100049. DOI: 10.1016/j.lanepe.2021.100049Chow F.C., Chok K.S. Colorectal liver metastases: an update on multidisciplinary approach. World J Hepatol 2019;11(2):150–72. DOI: 10.4254/wjh.v11.i2.150Bregni G., Giasafaki P., Leurquin B. et al. 5MO – Individual patient data (IPD) meta-analysis of randomized phase III trials (RP3) of chemotherapy for resectable colorectal cancer liver metastases (CRCLM): EORTC RP-2145. Ann of Oncol 2024:35(Suppl_1):S1–74. DOI: 10.1016/annonc/annonc1477Rahbari N.N., Reissfelder C., Schulze-Bergkamen H. et al. Adjuvant therapy after resection of colorectal liver metastases: the predictive value of the MSKCC clinical risk score in the era of modern chemotherapy. BMC Cancer 2014;14:174. DOI: 10.1186/1471-2407-14-174Ros J., Salva F., Dopazo C. et al. Liver transplantation in metastatic colorectal cancer: are we ready for it? Br J Cancer 2023;128(10):1797–806. DOI: 10.1038/s41416-023-02213-1Sasaki K., Ruffolo L.I., Kim M.H. et al. The current state of liver transplantation for colorectal liver metastases in the United States: A call for standardized reporting. Ann Surg Oncol 2023;30(5):2769–77. DOI: 10.1245/s10434-023-13147-6Adam R., Piedvache C., Chiche L. et al. Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): results from a multicentre, open-label, prospective, randomised controlled trial. Lancet 2024;404(10458):1107–18. DOI: 10.1016/S0140-6736(24)01595-2Tsukanov A.S., Shelygin Y.A., Semenov D.A. et al. Lynch syndrome: current status. Medicinskaya genetika = Medical Genetics 2017;16(2):11–8. (In Russ.).Цуканов А.С., Шелыгин Ю.А., Семенов Д.А. и др. Синдром Линча. Современное состояние проблемы. Медицинская генетика 2017;16(2):11–8.Ciardiello D., Bielo L.B., Napolitano S. et al. Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAFV600E wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trial. Ann Oncol 2024:S0923-7534(24)03914-0. DOI: 10.1016/j.annonc.2024.08.2334Fedyanin M.Yu., Elsnukaeva Kh.Kh-M., Demidova I.A. et al. Incidence and prognostic factors in patents (PTS) with mutant braf (MBRAF) metastatic colorectal cancer (MCRC) in Russia. Medicinskij sovet = Medical Council 2021;(S4):52–63. (In Russ.). DOI: 10.21518/2079-701X-2021-4S-52-63Федянин М.Ю., Эльснукаева Х.Х.-М., Демидова И.А. и др. Колоректальный рак с мутацией в гене BRAF в Российской Федерации: эпидемиология и клинические особенности. Результаты многоцентрового исследования. Медицинский совет 2021;(S4):52–63. DOI: 10.21518/2079-701X-2021-4S-52-63Kotani D., Bando H., Taniguchi H. et al. Efficacy and safety of combination therapy with binimetinib, encorafenib, and cetuximab for BRAF non-V600E mutated metastatic colorectal cancer: Results from a phase 2 BIG BANG trial (EPOC1703). J Clin Oncol 2024;42(16_suppl):3585. DOI: 10.1200/JCO.2024.42.16_suppl.3585Mulkidjan R.S., Saitova E.S., Preobrazhenskaya E.V. et al. ALK, ROS1, RET and NTRK1-3 gene fusions in colorectal and noncolorectal microsatellite-unstable cancers. Int J Mol Sci 2023;24(17):13610. DOI: 10.3390/ijms241713610Wang F., Zhao Q., Wang Y.-N. et al. Evaluation of POLE and POLD1 mutations as biomarkers for immunotherapy outcomes across multiple cancer types. JAMA Oncol 2019;5(10):1504–6. DOI: 10.1001/jamaoncol.2019.2963.Shiu K., André T., Kim T.W. et al. Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the randomized phase III KEYNOTE-177 study. Annals of Oncology 2023;34(suppl_2):S1254–335. DOI: 10.1016/S0923-7534(23)04149-2Lenz H.-J., Lonardi S., Elez E. et al. Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repairdeficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Expanded efficacy analysis from CheckMate 8HW. J Clin Oncol 2024;42(16_suppl). DOI: 10.1200/JCO.2024.42.16_suppl.3503Chen M., Wang Z., Liu Z. et al. PD-1/PD-L1 Inhibitor plus chemotherapy versus PD-1/PD-L1 inhibitor in microsatellite instability gastrointestinal cancers: A multicenter retrospective study. JCO Precis Oncol 2023:7:e2200463. DOI: 10.1200/PO.22.00463de Langen A.J., Johnson M.L., Mazieres J. et al. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial. Lancet 2023;401(10378):733–46. DOI: 10.1016/S0140-6736(23)00221-0Fakih M.G., Salvatore L., Esaki T. et al. Sotorasib plus panitumumab in refractory colorectal cancer with mutated KRASG12C. N Engl J Med 2023;389(23):2125–39. DOI: 10.1056/NEJMoa2308795Siena S., Yamaguchi K., Rodriguez J.C.R. et al. Sotorasib (soto), panitumumab (pani) and FOLFIRI in the first-line (1L) setting for KRASG12C–mutated metastatic colorectal cancer (mCRC): Safety and efficacy analysis from the phase Ib CodeBreaK 101 study. Annals of Oncol 2024;35(suppl_2):S428–81. DOI: 10.1016/annonc/annonc1588Yaeger R., Weiss J., Pelster M.S. et al. Adagrasib with or without cetuximab in colorectal cancer with mutated KRASG12C. N Engl J Med 2023;388(1):44–54. DOI: 10.1056/NEJMoa2212419Raghav K., Siena S., Takashima A. et al. Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial. Lancet Oncol 2024;25(9):1147–62. DOI: 10.1016/S1470-2045(24)00380-2Tabernero J., Grothey A., Van Cutsem E. et al. Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study. J Clin Oncol 2021;39(4):273–84. DOI: 10.1200/JCO.20.02088Kopetz S., Yoshino T., Kim T.W. et al. BREAKWATER safety leadin (SLI): Encorafenib + cetuximab (EC) ± chemotherapy for firstline (1L) treatment (tx) of BRAF V600E-mutant (BRAF V600E) metastatic colorectal cancer (mCRC). J Clin Oncol 2022; 40(4_suppl):134. DOI: 10.1200/JCO.2022.40.4_suppl.134Cherny N.I., Dafni U., Bogaerts J. et al. ESMO-magnitude of clinical benefit scale version 1.1. Ann Oncol 2017;28(10):2340–66. DOI: 10.1093/annonc/mdx310.Krech R., Peters S., Kroemer H. et al. Tobacco cessation and the role of ESMO and medical oncologists: addressing the specific needs of cancer patients in times of the COVID-19 pandemic. ESMO Open 2023;8(3):101579. DOI: 10.1016/j.esmoop.2023.101579Shields P.G., Bierut L., Arenberg D. et al. Smoking cessation, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2023;21(3):297–322. DOI: 10.6004/jnccn.2023.0013Choy K.T., Lam K., Kong J.C. Exercise and colorectal cancer survival: an updated systematic review and meta-analysis. Int J Colorectal Dis 2022;37(8):1751–8. DOI: 10.1007/s00384-022-04224-5Agirre-Elordui S., Fernández-Landa J., Olasagasti-Ibargoien J. et al. Physical activity maintenance in colorectal cancer survivors after an exercise intervention applying behaviour change techniques: a systematic review and meta-analysis. J Cancer Surviv 2024. DOI: 10.1007/s11764-024-01654-8Walter V., Jansen L., Hoffmeister M., Brenner H. Smoking and survival of colorectal cancer patients: systematic review and meta-analysis. Ann Oncol 2014;25(8):1517–25. DOI: 10.1093/annonc/mdu040Alwers E., Carr P.R., Banbury B. Smoking behavior and prognosis after colorectal cancer diagnosis: a pooled analysis of 11 studies. JNCI Cancer Spectr 2021;5(5):p.pkab077. DOI: 10.1093/jncics/pkab077Badiani S., Diab J., Woodford E.R. Impact of preoperative smoking on patients undergoing right hemicolectomies for colon cancer. Langenbecks Arch Surg 2022;407(5):2001–9. DOI: 10.1007/s00423-022-02486-9. Erratum in: Langenbecks Arch Surg 2022;407(8):3889. DOI: 10.1007/s00423-022-02528-2Park E.R., Perez G.K., Regan S. et al. Effect of sustained smoking cessation counseling and provision of medication vs shorter-term counseling and medication advice on smoking abstinence in patients recently diagnosed with cancer: A randomized clinical trial. JAMA 2020;324(14):1406–18. DOI: 10.1001/jama.2020.14581Scholten P.R., Stalpers L.J., Bronsema I. et al. The effectiveness of smoking cessation interventions after cancer diagnosis: a systematic review and meta-analysis. J Cancer Policy 2024;39:100463. DOI: 10.1016/j.jcpo.2023.100463Haussmann H.J., Fariss M.W. Comprehensive review of epidemiological and animal studies on the potential carcinogenic effects of nicotine per se. Critical reviews in toxicology 2016;46(8):701–34. DOI: 10.1080/10408444.2016.1182116Hartmann-Boyce J., McRobbie H., Butler A.R. et al. Electronic cigarettes for smoking cessation. Cochrane Database Syst Rev 2022;9:CD010216. DOI: 10.1002/14651858.CD010216.pub5Lindson N., Butler A.R., McRobbie H. et al. Electronic cigarettes for smoking cessation. Cochrane Database of Syst Rev 2024;1(1):CD010216. DOI: 10.1002/14651858.CD010216.pub8Ansari S.M., Hession P.S., David M. et al. Impact of switching from cigarette smoking to tobacco heating system use on biomarkers of potential harm in a randomized trial. Biomarkers 2024;29(5):298–314. DOI: 10.1080/1354750X.2024.2358318Hatsukami D.K., Benowitz N.L., Rennard S.I. et al. Biomarkers to assess the utility of potential reduced exposure tobacco products. Nicotine Tob Res 2006;8(4):600–22. DOI: 10.1080/14622200600858166Xue J., Yang S., Seng S. Mechanisms of cancer induction by tobacco-specific NNK and NNN. Cancers (Basel) 2014;6(2):1138–56. DOI: 10.3390/cancers6021138Yuan J.M., Butler L.M., Stepanov I., Hecht S.S. Urinary tobacco smoke-constituent biomarkers for assessing risk of lung cancer. Cancer Res 2014;74(2):401–11. DOI: 10.1158/0008-5472.CAN-13-3178Hoang T., Kim H., Kim J. Dietary intake in association with allcause mortality and colorectal cancer mortality among colorectal cancer survivors: A systematic review and meta-analysis of prospective studies. Cancers (Basel) 2020;12(11):3391. DOI: 10.3390/cancers12113391Chan D.S.M., Cariolou M., Markozannes G. et al. Post-diagnosis dietary factors, supplement use and colorectal cancer prognosis: A Global Cancer Update Programme (CUP Global) systematic literature review and meta-analysis. Int J Cancer 2024;155(3): 445–70. DOI: 10.1002/ijc.34906